Research and Markets - Intellectual Property Strategies involved in Development of Pharmaceuticals Analysed

Research and Markets (researchandmarkets.com) has announced the addition of Intellectual Property Strategies for Pharmaceutical Development to their offering.

(PRWEB) November 20, 2004 -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Intellectual Property Strategies for Pharmaceutical Development to their offering.

According to Tufts University in 2003, a new chemical entity (NCE) costs on average US$897 million to develop, including cost of post-approval research (rising from US$803 M in 2001). An NCE can often be copied very easily once it is on the market. Lesser, but still considerable costs apply to the development of new forms of an NCE, and to new formulations and uses of existing NCEs. To justify such investments the research-based industry, including those who develop new formulations and uses, needs exclusive rights for a reasonable period.

This exclusivity allows the investors to recoup their costs, and, if they are lucky, the costs of their failed developments. If they are very lucky and skillful they may make a considerable amount of money. Without the protection provided by various forms of intellectual property, mainly patents and regulatory exclusivities, investments in this highly risky business would be unlikely.

This report provides an introduction to the intellectual property strategies involved in the development of pharmaceuticals from the discovery of an NCE, through to its launch, with details and advice on the appropriate decisions and actions. The report also deals with the different types of inventions that may occur.

This report targets:
- Patent attorneys who are in either industrial or private practice and who deal with pharmaceutical inventions
- Research workers and managers in the pharmaceutical industry
- Business executives and lawyers who will be dealing with the licensing of pharmaceutical inventions
- Individuals and companies involved in the development of straight generic products, and those developing innovative products based on existing compounds (so called 'branded generics' or 'super generics') who are trying to find ways through the protections put up by the research based industry
- Pharmaceutical and biotechnology investors
- Researchers, business development managers and technology transfer officers in universities and institutions

Similar people in the agrochemical industry will find much of relevance to their business in the report (though the report does not deal directly with agrochemical inventions)

Topics covered include:
- Types of IP in pharmaceutical development
- To get a patent
- General Strategy

For more information visit http://www.researchandmarkets.com/reports/c9614

###